Melanoma Trial

Merkel Cell, After Surgery

Pembrolizumab Compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer

OR

Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab (STAMP), a Phase III Trial

 

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

    • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.

Patient Educational Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.

    • Patient Frequently Asked Questions: Frequently asked question handout about treatment, eligibility criteria, and potential enrollment issues with answers in lay language.

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

ClinicalTrials.gov ID: NCT03712605

Return to Home Page | Review Other Active Trials